Evotec receives CARB-X funding

Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8,4m funding from CARB-X for co-development of a first-in-class antibiotic.

Read more

BioNTech and Fosun Pharma kick off Chinese COVID-19 trials

BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.

Read more

Roche’s IL-6 receptor blocker fails in Phase III

Roche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.

Read more

AMR: Big Pharma sets up US$1bn Fund

After leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).

Read more

VarmX bags €32m in Series B round

Leiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.

Read more